Transverse Medical, a Denver, CO-based early-stage medical device technology company, raised $10M in Series B2 funding.
Backers included participation from the company’s legacy lead investor, and Series B1 investors.
The company intends to use the funds to expand operational infrastructure and grow its engineering, regulatory, and operating teams.
Led by CEO and President Eric Goslau, Transverse Medical is focused on the development of the Point-Guard cerebral embolic protection medical device for use during transcatheter aortic valve replacements (TAVR) to protect patients from embolic debris (particles) that are dislodged and released (debris shower) into the cerebral blood flow that could lead to periprocedural stroke as a result of the TAVR procedure.
FinSMEs
29/04/2025